ALPHARETTA, Ga., Nov. 12, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Michael Greiner, interim chief executive officer, will participate in an analyst-led fireside chat at the Stifel 2024 Healthcare Conference at the Lotte New York Palace in New York on Tuesday, Nov. 19 at approximately 3:35 p.m. ET.A webcast of the conference presentation will be available on the Investors section of the Avanos Medical website and will be archived on that site.About Avanos Medical, Inc.Avano ...

文章核心观点 - CMS发布2025年最终医保规则 公司两款产品符合要求可单独获支付 [1][3] 根据相关目录分别进行总结 关于NOPAIN法案 - NOPAIN法案是2023年综合拨款法案一部分 旨在增加患者获取非阿片类药物和设备机会 [2] 关于Avanos公司产品 - 公司的ON - Q和ambIT输注系统符合要求 2025年1月1日起使用这两款产品的机构可单独获医保报销 [3] - 两款产品各有独特的HCPCS编码可用于单独支付 [4] - ON - Q和ambIT输注系统支付限额均为2284.98美元 2025年1月1日起可用于索赔提交 [5] - 公司产品是该政策下首批且唯一的输注镇痛泵 政策旨在减少术后对阿片类药物依赖 [6] - 公司临时CEO称赞CMS决定 公司产品可有效减少术后阿片类药物使用 [7] 关于Avanos公司 - 是医疗技术公司 致力于提供医疗设备解决方案 [9]

Advancement to reduce dislodgement in feeding tube retention systems ALPHARETTA, Ga., Nov. 5, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced the launch of its newly designed CORGRIP SR Nasogastric/Nasointestinal Tube Retention System, further expanding its comprehensive Enteral Feeding portfolio.The new CORGRIP SR system, featuring a monofilament thread, is a nasal bridle solution designed to offer numerous advantages over tape. CORGRIP SR is designed to reduce the risk of dislodgeme ...

Avanos Medical, Inc. (AVNS) reported third-quarter 2024 adjusted earnings per share (EPS) from continuing operations of 36 cents, up 20% year over year. The bottom line met the Zacks Consensus Estimate.GAAP EPS from continuing operations in the quarter under review was 12 cents against the year-ago reported loss of 19 cents per share.RevenuesRevenues totaled $170.4 million, down 0.5% year over year. The metric missed the Zacks Consensus Estimate by 2.7%.Organic sales were up 1.1% year over year.Per manageme ...

财务状况 - 公司总资产为 XXX 亿元 [1] - 公司总负债为 XXX 亿元 [1] - 公司净资产为 XXX 亿元 [1] - 公司资产负债率为 XX% [1] 营业收入 - 公司本期营业收入为 XXX 亿元 [2] - 公司营业收入同比增长 XX% [2] - 公司主营业务收入占营业收入的 XX% [2] 盈利能力 - 公司本期净利润为 XXX 亿元 [3] - 公司净利润同比增长 XX% [3] - 公司毛利率为 XX% [3] - 公司净利率为 XX% [3] 现金流 - 公司经营活动产生的现金流量净额为 XXX 亿元 [4] - 公司投资活动产生的现金流量净额为 XXX 亿元 [4] - 公司筹资活动产生的现金流量净额为 XXX 亿元 [4] - 公司现金及现金等价物净增加额为 XXX 亿元 [4]

财务数据和关键指标变化 - 公司在2024年第三季度的销售额约为1.7亿美元，调整后的每股收益为0.36美元，调整后的EBITDA约为3100万美元，调整后的EBITDA利润率接近18% [16][28] - 调整后的毛利率为58%，与去年持平，预计第四季度调整后的毛利率将达到约59% [27][28] - 自由现金流在第三季度为2000万美元，预计第四季度将产生约3000万美元的自由现金流 [29] 各条业务线数据和关键指标变化 - 消化健康业务在第三季度实现了近3%的有机增长，主要得益于NeoMed产品线的双位数增长 [17][18] - 疼痛管理和恢复业务的有机销售增长略超过1%，但外科疼痛产品线表现不佳，主要受到供应链问题的影响 [19][20] - Game Ready产品线连续第三个季度实现双位数增长，预计第四季度的绝对收入将与前三个季度持平 [23][45] 各个市场数据和关键指标变化 - 在北美市场，COOLIEF产品线的表现有所放缓，但国际市场的增长势头良好，特别是在英国和日本 [22][44] - NeoMed产品线在北美的ENFit转换需求强劲，预计将继续推动增长 [18][42] 公司战略和发展方向和行业竞争 - 公司正在实施一项三年转型计划，旨在优化产品组合、重塑商业运营并改善利润率 [13][31] - 公司计划继续追求与其回报标准相符的战略并购机会，并进行资本的机会性回购 [30][50] 管理层对经营环境和未来前景的评论 - 管理层对第三季度的表现表示满意，但承认未能实现中等单一数字的有机增长目标，主要受到外科疼痛产品线的影响 [14][19] - 对于未来，管理层对ON-Q产品的前景持乐观态度，尤其是与No Pain Act相关的潜在补偿变化 [36][46] 其他重要信息 - 公司在第三季度完成了与AirLife的两项呼吸健康业务的转让，标志着转型计划的重要里程碑 [13][32] - 公司在FDA批准了CORGRIP SR鼻用支架系统，进一步增强了其产品组合 [33] 问答环节所有提问和回答 问题: 关于ON-Q产品线的供应限制，预计会持续多久？ - 管理层表示，ON-Q的主要供应挑战在第三季度的前半段已经解决，但错过的程序无法追回，影响了季度业绩 [35] 问题: 对于公司的长期目标和2025年的增长预期如何？ - 管理层未对2025年做出具体评论，但表示整体产品组合表现良好，需评估ON-Q的未来增长潜力 [37][39] 问题: 2025年的主要销售推动因素有哪些？ - 管理层提到消化健康业务的核心产品线将支持增长，并计划推出新产品以维持市场份额 [41][42] 问题: Game Ready产品的增长驱动因素是什么？ - 管理层指出，虽然存在基数效应，但Game Ready的绝对收入仍在增长，并计划通过直接面向消费者的策略进一步推动增长 [47][48]

Avanos Medical (AVNS) came out with quarterly earnings of $0.36 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.30 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this medical technology company would post earnings of $0.29 per share when it actually produced earnings of $0.34, delivering a surprise of 17.24%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Avanos Med ...

AVANOS Investor Contact: Michael Greiner Avanos Medical, Inc. 470-562-2692 Investor.Relations@Avanos.com Media Contact: Katrine Kubis Avanos Medical, Inc. CorporateCommunications@Avanos.com Avanos Medical, Inc. Announces Third Quarter 2024 Results, retirement of CEO ALPHARETTA, Ga., October 30, 2024/PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported third quarter 2024 financial results and announced the retirement of its CEO, Joe Woody. Gary Blackford, Avanos Board Chairman, noted "Joe has deci ...

ALPHARETTA, Ga., Oct. 30, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported third quarter 2024 financial results and announced the retirement of its CEO, Joe Woody. Gary Blackford, Avanos Board Chairman, noted, "Joe has decided to retire after leading Avanos for the past seven years. Joe has agreed to assist the Company in the transition of leadership, and will continue to consult with the Company through April of next year. Avanos is better positioned financially and organizationally to ...

ALPHARETTA, Ga., Oct. 23, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the third quarter 2024 on Wednesday, Oct. 30 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day.The conference call will be hosted by Joe Woody, chief executive officer, and Michael Greiner, senior vice president, chief financial officer, and chief transformation officer.To join ...